Skip to main content
main-content
Erschienen in: Breast Cancer Research and Treatment 1/2019

06.02.2019 | Clinical trial

High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer

verfasst von: Ulrich Bick, Christoph Engel, Barbara Krug, Walter Heindel, Eva M. Fallenberg, Kerstin Rhiem, David Maintz, Michael Golatta, Dorothee Speiser, Dorothea Rjosk-Dendorfer, Irina Lämmer-Skarke, Frederic Dietzel, Karl Werner Fritz Schäfer, Elena Leinert, Stefanie Weigel, Stephanie Sauer, Stefanie Pertschy, Thomas Hofmockel, Anne Hagert-Winkler, Karin Kast, Anne Quante, Alfons Meindl, Marion Kiechle, Markus Loeffler, Rita K. Schmutzler, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To report on 10 years of high-risk service screening with annual MRI in the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

Methods

A cohort of 4,573 high-risk, previously unaffected women (954 BRCA1 carriers, 598 BRCA2 carriers, 3021 BRCA1/2 non-carriers) participating in the GC-HBOC surveillance program was prospectively followed. Screening outcomes for 14,142 screening rounds with MRI between 2006 and 2015 were analyzed and stratified by risk group, type of screening round, and age.

Results

A total of 221 primary breast cancers (185 invasive, 36 in situ) were diagnosed within 12 months of an annual screening round with MRI. Of all cancers, 84.5% (174/206, 15 unknown) were stage 0 or I. In BRCA1 carriers, 16.9% (10/59, 5 unknown) of all incident cancers (screen-detected and interval cancers combined) and in BRCA2 carriers 12.5% (3/24, 4 unknown) were stage IIA or higher, compared to only 4.8% (2/42, 2 unknown) in high-risk BRCA1/2 non-carriers. Program sensitivity was 89.6% (95% CI 84.9–93.0) with no significant differences in sensitivity between risk groups or by age. Specificity was significantly lower in the first screening round (84.6%, 95% CI 83.6–85.7) than in subsequent screening rounds (91.1%, 95% CI 90.6–91.7), p < 0.001. Cancer detection rates (CDRs) and as a result positive predictive values were strongly dependent on type of screening round, risk group and patient age. CDRs ranged from 43.5‰ (95% CI 29.8–62.9) for the first screening round in BRCA2 carriers to 2.9‰ (95% CI 1.3–6.3) for subsequent screening rounds in high-risk non-carriers in the age group 30 to 39 years.

Conclusions

High-risk screening with MRI was successfully implemented in the GC-HBOC with high sensitivity and specificity. Risk prediction and inclusion criteria in high-risk non-carriers need to be adjusted to improve CDRs and thus screening efficacy in these patients.
Literatur
1.
Zurück zum Zitat Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, Brca Consortium BC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://​doi.​org/​10.​1001/​jama.​2017.​7112 CrossRefPubMed Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, Brca Consortium BC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://​doi.​org/​10.​1001/​jama.​2017.​7112 CrossRefPubMed
2.
Zurück zum Zitat Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679 CrossRefPubMed Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679 CrossRefPubMed
4.
Zurück zum Zitat Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH (2015) Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age>/= 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol 33(4):349–356. https://​doi.​org/​10.​1200/​JCO.​2014.​56.​6232 CrossRefPubMed Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH (2015) Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age>/= 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol 33(4):349–356. https://​doi.​org/​10.​1200/​JCO.​2014.​56.​6232 CrossRefPubMed
5.
Zurück zum Zitat Vreemann S, Gubern-Merida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM (2018) Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk. Radiology 286(2):443–451. https://​doi.​org/​10.​1148/​radiol.​2017170458 CrossRefPubMed Vreemann S, Gubern-Merida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM (2018) Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk. Radiology 286(2):443–451. https://​doi.​org/​10.​1148/​radiol.​2017170458 CrossRefPubMed
6.
Zurück zum Zitat Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. preventive services task force recommendation. Ann Intern Med 160(4):255–266. https://​doi.​org/​10.​7326/​M13-1684 CrossRefPubMed Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. preventive services task force recommendation. Ann Intern Med 160(4):255–266. https://​doi.​org/​10.​7326/​M13-1684 CrossRefPubMed
7.
Zurück zum Zitat Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teule A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319–327. https://​doi.​org/​10.​1007/​s10549-016-3805-0 CrossRefPubMedPubMedCentral Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teule A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319–327. https://​doi.​org/​10.​1007/​s10549-016-3805-0 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory G (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89 CrossRefPubMed Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, American Cancer Society Breast Cancer Advisory G (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89 CrossRefPubMed
9.
Zurück zum Zitat National Institute for Health and Care Excellence (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 41 and 14. (Clinical guideline 164). http://​guidance.​nice.​org.​uk/​CG164 National Institute for Health and Care Excellence (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Update of clinical guideline 41 and 14. (Clinical guideline 164). http://​guidance.​nice.​org.​uk/​CG164
10.
Zurück zum Zitat Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, Evans A, Fallenberg E, Forrai G, Fuchsjager MH, Gilbert FJ, Helbich TH, Heywang-Kobrunner SH, Camps-Herrero J, Kuhl CK, Martincich L, Pediconi F, Panizza P, Pina LJ, Pijnappel RM, Pinker-Domenig K, Skaane P, Sardanelli F, European Society of Breast Imaging wlrbED-TEBCC (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25(12):3669–3678. https://​doi.​org/​10.​1007/​s00330-015-3807-z CrossRefPubMedPubMedCentral Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, Evans A, Fallenberg E, Forrai G, Fuchsjager MH, Gilbert FJ, Helbich TH, Heywang-Kobrunner SH, Camps-Herrero J, Kuhl CK, Martincich L, Pediconi F, Panizza P, Pina LJ, Pijnappel RM, Pinker-Domenig K, Skaane P, Sardanelli F, European Society of Breast Imaging wlrbED-TEBCC (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25(12):3669–3678. https://​doi.​org/​10.​1007/​s00330-015-3807-z CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH (2000) Breast MR Imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279 CrossRefPubMed Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH (2000) Breast MR Imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279 CrossRefPubMed
14.
Zurück zum Zitat Schmutzler RK, Rhiem K, Breuer P, Wardelmann E, Lehnert M, Coburger S, Wappenschmidt B (2006) Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. Eur J Cancer Prev 15(6):483–489 CrossRefPubMed Schmutzler RK, Rhiem K, Breuer P, Wardelmann E, Lehnert M, Coburger S, Wappenschmidt B (2006) Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. Eur J Cancer Prev 15(6):483–489 CrossRefPubMed
15.
Zurück zum Zitat Claus EB, Risch N, Thompson WD (1994) Autosomal domonant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73:643–651 CrossRefPubMed Claus EB, Risch N, Thompson WD (1994) Autosomal domonant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73:643–651 CrossRefPubMed
16.
Zurück zum Zitat Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, Lenoir G, Lynch H (1995) Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64(6):394–398 CrossRefPubMed Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, Lenoir G, Lynch H (1995) Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64(6):394–398 CrossRefPubMed
18.
Zurück zum Zitat Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 127:24–30. https://​doi.​org/​10.​1038/​bjc.​2012.​204 CrossRef Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 127:24–30. https://​doi.​org/​10.​1038/​bjc.​2012.​204 CrossRef
19.
Zurück zum Zitat American College of Radiology (2003) ACR BI-RADS®. breast imaging and reporting data system, breast imaging atlas. mammography, breast ultrasound, magnetic resonance imaging. American College of Radiology, Reston American College of Radiology (2003) ACR BI-RADS®. breast imaging and reporting data system, breast imaging atlas. mammography, breast ultrasound, magnetic resonance imaging. American College of Radiology, Reston
20.
Zurück zum Zitat Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8):857–872 CrossRefPubMed Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8):857–872 CrossRefPubMed
22.
Zurück zum Zitat Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24(8):2029–2035. https://​doi.​org/​10.​1093/​annonc/​mdt134 CrossRefPubMed Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol 24(8):2029–2035. https://​doi.​org/​10.​1093/​annonc/​mdt134 CrossRefPubMed
23.
Zurück zum Zitat Heijnsdijk EAM, Warner E, Gilbert FJ, Tilanus-Linthorst MMA, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RML, Hill KA, Hoogerbrugge N, Wasser MNJM, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJT, Klijn JGM, Plewes DB, Leach MO, de Koning HJ (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI Screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21(9):1458–1468. doi: https://​doi.​org/​10.​1158/​1055-9965.​Epi-11-1196 CrossRefPubMed Heijnsdijk EAM, Warner E, Gilbert FJ, Tilanus-Linthorst MMA, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RML, Hill KA, Hoogerbrugge N, Wasser MNJM, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJT, Klijn JGM, Plewes DB, Leach MO, de Koning HJ (2012) Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI Screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 21(9):1458–1468. doi: https://​doi.​org/​10.​1158/​1055-9965.​Epi-11-1196 CrossRefPubMed
25.
Zurück zum Zitat Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28(36):5265–5273 CrossRefPubMed Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28(36):5265–5273 CrossRefPubMed
27.
Zurück zum Zitat Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, Morassut S, Di Maggio C, Cilotti A, Martincich L, Calabrese M, Zuiani C, Preda L, Bonanni B, Carbonaro LA, Contegiacomo A, Panizza P, Di Cesare E, Savarese A, Crecco M, Turchetti D, Tonutti M, Belli P, Maschio AD (2011) Multicenter Surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol 46(2):94–105 CrossRefPubMed Sardanelli F, Podo F, Santoro F, Manoukian S, Bergonzi S, Trecate G, Vergnaghi D, Federico M, Cortesi L, Corcione S, Morassut S, Di Maggio C, Cilotti A, Martincich L, Calabrese M, Zuiani C, Preda L, Bonanni B, Carbonaro LA, Contegiacomo A, Panizza P, Di Cesare E, Savarese A, Crecco M, Turchetti D, Tonutti M, Belli P, Maschio AD (2011) Multicenter Surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. Invest Radiol 46(2):94–105 CrossRefPubMed
29.
30.
Zurück zum Zitat Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG (2007) Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 102(3):357–363 CrossRefPubMed Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG (2007) Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 102(3):357–363 CrossRefPubMed
31.
Zurück zum Zitat Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437 CrossRefPubMed Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437 CrossRefPubMed
32.
33.
Zurück zum Zitat Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB (2011) Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 17(1):9–17 CrossRefPubMed Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB (2011) Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 17(1):9–17 CrossRefPubMed
Metadaten
Titel
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer
verfasst von
Ulrich Bick
Christoph Engel
Barbara Krug
Walter Heindel
Eva M. Fallenberg
Kerstin Rhiem
David Maintz
Michael Golatta
Dorothee Speiser
Dorothea Rjosk-Dendorfer
Irina Lämmer-Skarke
Frederic Dietzel
Karl Werner Fritz Schäfer
Elena Leinert
Stefanie Weigel
Stephanie Sauer
Stefanie Pertschy
Thomas Hofmockel
Anne Hagert-Winkler
Karin Kast
Anne Quante
Alfons Meindl
Marion Kiechle
Markus Loeffler
Rita K. Schmutzler
the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
Publikationsdatum
06.02.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05152-9

Weitere Artikel der Ausgabe 1/2019

Breast Cancer Research and Treatment 1/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.